Amplia Therapeutics Limited (ASX:ATX): Narmafotinib Program Expands Across Pancreatic, Ovarian and Lung Cancer

Aditi Sarkar

06 October 2026 03:48 PM AEDT

Amplia Therapeutics Limited (ASX:ATX): Narmafotinib Program Expands Across Pancreatic, Ovarian and Lung Cancer

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Amplia Therapeutics Limited (ASX:ATX) is progressing narmafotinib, its focal adhesion kinase inhibitor, across pancreatic, ovarian and lung cancer programs.
The protocol for the Phase 2 PRROSE ovarian cancer study has been finalised, with approximately 26 patients expected to participate across Australia and New Zealand.
Amplia entered a clinical trial collaboration and Supply agreement with Eli Lilly to evaluate narmafotinib with olomorasib in advanced non-small cell lung cancer.
At the time of writing this article, Amplia Therapeutics Limited (ASX:ATX) was trading at AUD 0.115, up 4.55% during today’s trading session.

At the time of writing this article, Amplia Therapeutics Limited (ASX:ATX) was trading at AUD 0.115, up 4.55% during today’s trading session. Amplia is an Australian pharmaceutical company developing focal adhesion kinase, or FAK, inhibitors for cancer and fibrosis. Its clinical development activities are centred on narmafotinib, with programs spanning pancreatic cancer and newer studies targeting ovarian and lung cancer. Recent company developments have broadened the clinical evaluation of narmafotinib while Amplia continues work on its pancreatic cancer development pathway. Amplia

Company Business

Amplia’s development pipeline is based on small-molecule inhibitors of FAK, a protein involved in cellular signalling and the tumour microenvironment. The company has identified cancer and fibrotic diseases as primary areas of development, with particular attention to cancers where fibrosis can influence disease progression and treatment response.

Narmafotinib is Amplia’s lead clinical candidate. The company has been evaluating the compound in pancreatic cancer and is extending development into additional cancer indications. Amplia also holds rights to another FAK inhibitor, AMP886, as part of its broader development portfolio.

Manufacturing has also been advanced to support clinical requirements. In January 2026, Amplia announced completion of its first large-scale narmafotinib Manufacturing campaign, producing approximately 13 kilograms of drug substance. The company said the supply was sufficient to support pancreatic cancer trials and other planned studies.

Recent Development

In September 2026, Amplia and the Australia New Zealand Gynaecological Oncology Group finalised the protocol for the PRROSE Phase 2 ovarian cancer study. The trial will evaluate narmafotinib in combination with standard-of-care chemotherapy in patients with high-grade serous ovarian cancer whose tumours have responded poorly to chemotherapy before planned surgery.

Approximately 26 patients are expected to be enrolled across selected clinical sites in Australia and New Zealand. Following completion of the protocol, ethics and site governance submissions are being progressed, with the parties targeting site activation and patient recruitment before the end of 2026.

Another development came in August 2026, when Amplia entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company. The planned Phase 1b/2b study will evaluate narmafotinib in combination with Lilly’s KRAS G12C inhibitor olomorasib as a second-line treatment for patients with advanced non-small cell lung cancer. The study is planned for sites in Australia and the United States.

Financial Performance and Sector Context

For the year ended 31 March 2026, Amplia reported a loss after tax of approximately AUD 7.71 million. Research and Development expenditure was approximately AUD 9.08 million, reflecting continued Investment in clinical programs and associated development activities.

Cash and cash equivalents at 31 March 2026 were approximately AUD 27.85 million. During the financial year, Amplia raised approximately AUD 27.65 million in capital, while the company reported no borrowings at year-end.

The financial profile reflects Amplia’s status as a clinical-stage pharmaceutical company. Its expenditure is primarily directed toward research, drug manufacture, clinical trials, regulatory work and intellectual property rather than commercial product sales.

Within the biotechnology sector, Drug Development remains dependent on clinical outcomes, regulatory engagement and sufficient funding to complete successive trial stages. For Amplia, the expansion of narmafotinib into multiple cancer studies increases the number of clinical programs requiring execution and monitoring.

Risks to Consider

Amplia is exposed to the clinical and regulatory risks associated with pharmaceutical development. Results from early or mid-stage Clinical Trials may not be replicated in larger studies, and regulatory authorities may require additional evidence before a treatment can advance.

Clinical recruitment, trial timelines, manufacturing requirements and study costs may also affect development schedules. The company remains dependent on available Capital to fund research and clinical activities while its drug candidates remain in development.

The widening narmafotinib program also requires Amplia to manage several clinical pathways across different cancer indications.

What to Watch Next

A key area to monitor is progress toward site activation and patient recruitment for the PRROSE ovarian cancer trial. Updates on the planned narmafotinib and olomorasib lung cancer study will also provide information on the expansion of the company’s clinical pipeline.

The pancreatic cancer program remains another central area of focus. In March 2026, Amplia reported mature ACCENT trial data showing five complete responses among 64 patients and median overall survival of 11.1 months in the study evaluating narmafotinib with chemotherapy.

Future financial updates will also provide information on research expenditure, clinical trial costs and cash resources as the development program progresses.

Key Insights

Amplia Therapeutics is advancing narmafotinib across several cancer indications while maintaining pancreatic cancer as a central clinical program. During 2026, the company broadened development through the PRROSE ovarian cancer study and a collaboration evaluating narmafotinib with olomorasib in lung cancer.

The company entered the period with funding available for continued clinical development, while research expenditure remains a significant component of its financial profile. Upcoming clinical trial commencements, patient recruitment, study results and cash utilisation remain the principal factors to monitor.

FAQs

Q:What does Amplia Therapeutics Limited develop?

A:Amplia develops focal adhesion kinase inhibitors for cancer and fibrosis, with narmafotinib as its lead clinical drug candidate.

Q:What cancer indications is narmafotinib being studied in?

A:Narmafotinib is being developed across pancreatic cancer, ovarian cancer and non-small cell lung cancer programs.

Q:What is the PRROSE study?

A:PRROSE is a planned Phase 2 study evaluating narmafotinib with standard-of-care chemotherapy in patients with high-grade serous ovarian cancer.

Q:What agreement did Amplia enter into with Eli Lilly?

A:Amplia entered a clinical trial collaboration and supply agreement to evaluate narmafotinib with Lilly’s KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer.

Q:What developments may be monitored next for Amplia Therapeutics?

A:Key areas include commencement and recruitment across the ovarian and lung cancer studies, progress in pancreatic cancer development, clinical results and the company’s cash expenditure.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.